Dr. Grint is currently CEO and a member of the board of directors of AmpliPhi Biosciences. Prior to becoming CEO of AmpliPhi, Dr. Grint was the President and CEO of Regulus Therapeutics, Inc., a company focused on the discovery and development of microRNA therapeutics. Dr. Grint has more than two decades of experience in biologics and small molecule development, including the successful commercialization of products in the infectious diseases, immunology and oncology therapeutic areas. Prior to his role at Regulus, he served as President of Cerexa, Inc. Dr. Grint has also served in senior management roles at Cerexa, Forest Research Institute, Kalypsys, Pfizer, IDEC Pharmaceuticals and Schering-Plough Corporation. He is a Fellow of the Royal College of Pathologists and is a member of numerous professional and medical societies. He holds a degree from St. Mary’s College, University of London and a medical degree from St. Bartholomew’s Hospital College, University of London.